BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G, Mitchell C. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365:21-31. [PMID: 21732834 DOI: 10.1056/nejmoa1011214] [Cited by in Crossref: 89] [Cited by in F6Publishing: 53] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Montepiedra G, Ramchandani R, Miyahara S, Kim S. A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches. Stat Med 2021;40:327-48. [PMID: 33105524 DOI: 10.1002/sim.8777] [Reference Citation Analysis]
2 Charan J, Goyal JP, Reljic T, Emmanuel P, Patel A, Kumar A. Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. Pediatr Infect Dis J 2018;37:773-80. [PMID: 29280783 DOI: 10.1097/INF.0000000000001879] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
3 Nunes MC, Kim S, Zeldow B, Violari A, Dittmer S, Cassim H, Thomas T, van Niekerk N, Cotton MF, Mitchell C, Adrian P, Madhi SA; P1041 team. Streptococcus pneumoniae colonization in pneumococcal vaccine-naïve human immunodeficiency virus-exposed infected and -uninfected South African children. Medicine (Baltimore) 2020;99:e19353. [PMID: 32118776 DOI: 10.1097/MD.0000000000019353] [Reference Citation Analysis]
4 Martinez L, Lo NC, Cords O, Hill PC, Khan P, Hatherill M, Mandalakas A, Kay A, Croda J, Horsburgh CR, Zar HJ, Andrews JR. Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies. Lancet Respir Med 2019;7:544-52. [PMID: 31078497 DOI: 10.1016/S2213-2600(19)30137-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 11.5] [Reference Citation Analysis]
5 Edessa D, Likisa J. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. PLoS One 2015;10:e0137492. [PMID: 26348618 DOI: 10.1371/journal.pone.0137492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
6 Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study. BMC Infect Dis 2020;20:294. [PMID: 32664847 DOI: 10.1186/s12879-020-05011-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tamandjou Tchuem C, Cotton MF, Nel E, Tedder R, Preiser W, Violari A, Bobat R, Hovind L, Aaron L, Montepiedra G, Mitchell C, Andersson MI. Viral hepatitis B and C in HIV-exposed South African infants. BMC Pediatr 2020;20:563. [PMID: 33357228 DOI: 10.1186/s12887-020-02479-x] [Reference Citation Analysis]
8 Xu H, Blair RV, Veazey RS, Wang X. Immunopathogenesis in HIV-associated pediatric tuberculosis. Pediatr Res 2021. [PMID: 33731810 DOI: 10.1038/s41390-021-01393-x] [Reference Citation Analysis]
9 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;:CD007545. [PMID: 23828580 DOI: 10.1002/14651858.CD007545.pub2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
10 Basu Roy R, Whittaker E, Seddon JA, Kampmann B. Tuberculosis susceptibility and protection in children. Lancet Infect Dis 2019;19:e96-e108. [PMID: 30322790 DOI: 10.1016/S1473-3099(18)30157-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 10.7] [Reference Citation Analysis]
11 Zeldow B, Kim S, McSherry G, Cotton MF, Jean-Philippe P, Violari A, Bobat R, Nachman S, Mofenson LM, Madhi SA, Mitchell C. Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041. Int J Tuberc Lung Dis 2017;21:38-45. [PMID: 28157463 DOI: 10.5588/ijtld.16.0149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Naranbhai V, Kim S, Fletcher H, Cotton MF, Violari A, Mitchell C, Nachman S, McSherry G, McShane H, Hill AV, Madhi SA. The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life. BMC Med 2014;12:120. [PMID: 25034889 DOI: 10.1186/s12916-014-0120-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
13 Adeniyi OV, Selanto-Chairman N, Owolabi EO, Ajayi AI, Kayembe DK, Ter Goon D, Gordana A, Lambert J. Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant women with HIV in the Eastern Cape, South Africa. BMC Public Health 2019;19:1407. [PMID: 31664978 DOI: 10.1186/s12889-019-7769-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Marquez C, Chamie G, Achan J, Luetkemeyer AF, Kyohere M, Okiring J, Dorsey G, Kamya MR, Charlebois ED, Havlir DV. Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda. Pediatr Infect Dis J 2016;35:524-9. [PMID: 26771662 DOI: 10.1097/INF.0000000000001062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
15 Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev 2017;8:CD006418. [PMID: 28850172 DOI: 10.1002/14651858.CD006418.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
16 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69:1-11. [PMID: 32053584 DOI: 10.15585/mmwr.rr6901a1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 54.0] [Reference Citation Analysis]
17 Beneri CA, Aaron L, Kim S, Jean-Philippe P, Madhi S, Violari A, Cotton MF, Mitchell C, Nachman S; P1041 team. Understanding NIH clinical case definitions for pediatric intrathoracic TB by applying them to a clinical trial. Int J Tuberc Lung Dis 2016;20:93-100. [PMID: 26688534 DOI: 10.5588/ijtld.14.0848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Kiser JJ, Zhu R, DʼArgenio DZ, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HI, Werely CJ, Fletcher CV. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Ther Drug Monit 2012;34:446-51. [PMID: 22695364 DOI: 10.1097/FTD.0b013e31825c4bc3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
19 Ndondoki C, Dicko F, Ahuatchi Coffie P, Kassi Eboua T, Ekouevi DK, Kouadio K, Edmond Aka A, Malateste K, Dabis F, Amani-Bosse C, Toure P, Leroy V; Paediatric IeDEA West African Working Group. Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa. J Int AIDS Soc 2014;17:18737. [PMID: 24894377 DOI: 10.7448/IAS.17.1.18737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Maritz ER, Montepiedra G, Liu L, Mitchell CD, Madhi SA, Bobat R, Violari A, Ogwu A, Hesseling AC, Cotton MF. Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study. Int J Tuberc Lung Dis 2016;20:1060-4. [PMID: 27393540 DOI: 10.5588/ijtld.15.0602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
21 Jones CE, Hesseling AC, Tena-Coki NG, Scriba TJ, Chegou NN, Kidd M, Wilkinson RJ, Kampmann B. The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination. AIDS 2015;29:155-65. [PMID: 25535752 DOI: 10.1097/QAD.0000000000000536] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
22 Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, Fletcher HA, Hanekom WA, Wood R, McShane H, Scriba TJ, Hatherill M. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med 2017;5:282-90. [PMID: 28215501 DOI: 10.1016/S2213-2600(17)30060-7] [Cited by in Crossref: 75] [Cited by in F6Publishing: 36] [Article Influence: 18.8] [Reference Citation Analysis]
23 Davies MA, Gibb D, Turkova A. Survival of HIV-1 vertically infected children. Curr Opin HIV AIDS 2016;11:455-64. [PMID: 27716730 DOI: 10.1097/COH.0000000000000303] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
24 Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, Rose P, van der Zalm M, Mbaba S, Van As D, Hanekom WA, Walzl G, Scriba TJ, McShane H, Hatherill M; MVA029 Study Team. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Clin Infect Dis 2018;66:554-63. [PMID: 29028973 DOI: 10.1093/cid/cix834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
25 Gupta A, Montepiedra G, Gupte A, Zeldow B, Jubulis J, Detrick B, Violari A, Madhi S, Bobat R, Cotton M, Mitchell C, Spector S; IMPAACT NWCS113 and P1041 Study Team. Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants. PLoS One 2016;11:e0148649. [PMID: 26872154 DOI: 10.1371/journal.pone.0148649] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
26 Okwara FN, Oyore JP, Were FN, Gwer S. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya - a cohort study. BMC Infect Dis 2017;17:623. [PMID: 28915796 DOI: 10.1186/s12879-017-2719-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Francisco-Cruz A, Mata-Espinosa D, Estrada-Parra S, Xing Z, Hernández-Pando R. Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis. Clin Exp Immunol. 2013;171:283-297. [PMID: 23379435 DOI: 10.1111/cei.12015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
28 Mao L, LaCourse SM, Kim S, Liu C, Ning B, Bao D, Fan J, Lyon CJ, Sun Z, Nachman S, Mitchell CD, Hu TY. Evaluation of a serum-based antigen test for tuberculosis in HIV-exposed infants: a diagnostic accuracy study. BMC Med 2021;19:113. [PMID: 34001096 DOI: 10.1186/s12916-021-01983-w] [Reference Citation Analysis]
29 Mudzviti T, Shamu T, Chimbetete C, Munengerwa T, Bote S, Pascoe M. Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort Study. Drugs Real World Outcomes 2019;6:37-42. [PMID: 30758779 DOI: 10.1007/s40801-019-0147-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Mecha J, Escudero JN, Hawn TR, John-Stewart G. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants. Clin Infect Dis 2021;73:e337-44. [PMID: 32564076 DOI: 10.1093/cid/ciaa827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Abuogi LL, Mwachari C, Leslie HH, Shade SB, Otieno J, Yienya N, Sanguli L, Amukoye E, Cohen CR. Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya. Int J Tuberc Lung Dis 2013;17:1291-7. [PMID: 24025380 DOI: 10.5588/ijtld.12.0740] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
32 Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA). HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. J Int AIDS Soc 2017;20:21327. [PMID: 28691438 DOI: 10.7448/IAS.20.1.21327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
33 Gasper MA, Hesseling AC, Mohar I, Myer L, Azenkot T, Passmore JS, Hanekom W, Cotton MF, Crispe IN, Sodora DL, Jaspan HB. BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial. JCI Insight 2017;2:e91963. [PMID: 28405623 DOI: 10.1172/jci.insight.91963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc 2012;15:17396. [PMID: 22905358 DOI: 10.7448/ias.15.2.17396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
35 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Escudero JN, Hawn TR, John-Stewart GC. Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent M. tuberculosis infection in HIV-exposed uninfected children. BMJ Open 2020;10:e034308. [PMID: 31969368 DOI: 10.1136/bmjopen-2019-034308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Venturini E, Turkova A, Chiappini E, Galli L, de Martino M, Thorne C. Tuberculosis and HIV co-infection in children. BMC Infect Dis 2014;14 Suppl 1:S5. [PMID: 24564453 DOI: 10.1186/1471-2334-14-S1-S5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 43] [Article Influence: 9.3] [Reference Citation Analysis]
37 Cranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, Wamalwa D, John-Stewart GC. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants. Pediatr Infect Dis J 2014;33:401-6. [PMID: 24378937 DOI: 10.1097/INF.0000000000000124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
38 Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis. 2014;14:91. [PMID: 24555539 DOI: 10.1186/1471-2334-14-91] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 8.9] [Reference Citation Analysis]
39 Rabie H, Goussard P. Tuberculosis and pneumonia in HIV-infected children: an overview. Pneumonia (Nathan) 2016;8:19. [PMID: 28702298 DOI: 10.1186/s41479-016-0021-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
40 Rabie H, Frigati L, Hesseling AC, Garcia-Prats AJ. Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children. J Int AIDS Soc 2015;18:20236. [PMID: 26639110 DOI: 10.7448/IAS.18.7.20236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
41 Hesseling AC, Jaspan HB, Black GF, Nene N, Walzl G. Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination. Int J Tuberc Lung Dis 2015;19:454-62. [PMID: 25860002 DOI: 10.5588/ijtld.14.0608] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
42 Modi S, Chiu A, Ng'eno B, Kellerman SE, Sugandhi N, Muhe L; Child Survival Working Group of the Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Child. Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings. AIDS 2013;27 Suppl 2:S159-67. [PMID: 24361625 DOI: 10.1097/QAD.0000000000000080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
43 Hesseling AC, Kim S, Madhi S, Nachman S, Schaaf HS, Violari A, Victor TC, McSherry G, Mitchell C, Cotton MF; IMPAACT P1041 Team. High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial. Int J Tuberc Lung Dis 2012;16:192-5. [PMID: 22236919 DOI: 10.5588/ijtld.10.0795] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
44 Cools P, van de Wijgert JHHM, Jespers V, Crucitti T, Sanders EJ, Verstraelen H, Vaneechoutte M. Role of HIV exposure and infection in relation to neonatal GBS disease and rectovaginal GBS carriage: a systematic review and meta-analysis. Sci Rep 2017;7:13820. [PMID: 29062060 DOI: 10.1038/s41598-017-13218-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
45 Frigati L, Archary M, Rabie H, Penazzato M, Ford N. Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease. Clin Infect Dis 2018;66:S147-51. [PMID: 29514237 DOI: 10.1093/cid/ciy013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
46 Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med 2016;14:50. [PMID: 27004529 DOI: 10.1186/s12916-016-0593-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
47 Ruck C, Reikie BA, Marchant A, Kollmann TR, Kakkar F. Linking Susceptibility to Infectious Diseases to Immune System Abnormalities among HIV-Exposed Uninfected Infants. Front Immunol 2016;7:310. [PMID: 27594857 DOI: 10.3389/fimmu.2016.00310] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
48 McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 2013;27:1933-40. [PMID: 24180002 DOI: 10.1097/qad.0b013e328360dbb4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
49 Cranmer LM, Draper HR, Mandalakas AM, Kim S, McSherry G, Krezinski E, Coetzee J, Mitchell C, Nachman S, van der Linde M, Cotton MF, Hesseling AC; IMPAACT P1041 Team. High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial. Pediatr Infect Dis J 2018;37:e254-6. [PMID: 29462104 DOI: 10.1097/INF.0000000000001946] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
50 Tchakoute CT, Hesseling AC, Kidzeru EB, Gamieldien H, Passmore JA, Jones CE, Gray CM, Sodora DL, Jaspan HB. Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants. J Infect Dis 2015;211:338-46. [PMID: 25108027 DOI: 10.1093/infdis/jiu434] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
51 Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K, Abdool Karim Q, Warimwe GM, McShane H, Fletcher H. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis 2014;209:500-9. [PMID: 24041796 DOI: 10.1093/infdis/jit494] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
52 Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, Hoffmann C, Dooley KE, Chaisson RE, Martinson N; TSHEPISO Study Team. Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis 2018;66:921-9. [PMID: 29028970 DOI: 10.1093/cid/cix851] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
53 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]